Medication info
Crestor 5 mg (Rosuvastatin Calcium)

Crestor 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
AstraZeneca Korea
Appearance
Yellow round film-coated tablets
Packaging
30 tablets/bottle, 30 tablets (15 tablets/PTP×2)
Approval status
Active

MFDS item code 200511256 · Approved 2005.12.29 · Insurance code 650700540

Summary

Main use
Improvement of dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; the dose may be adjusted to the maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled with this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients.
Child dose
Age 10 ~ 17 years: The usual dose range is 5mg ~ 20 mg once daily. (There are no clinical data on administration of doses higher than 20mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Improvement of dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
View approved original text

This medication is used as an adjunct in patients with primary hypercholesterolemia and mixed dyslipidemia when diet and exercise alone are not sufficient. In patients with homozygous familial hypercholesterolemia, it is used alongside diet or other lipid-lowering therapies to enhance effectiveness. It also helps lower total cholesterol and LDL cholesterol in patients with hypercholesterolemia, slowing the progression of atherosclerosis. It can be used as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia who meet specific criteria. It is also utilized as an adjunct to diet in patients with primary dysbetalipoproteinemia and contributes to reducing the risk of stroke, myocardial infarction, and arterial revascularization in adult patients at high risk for cardiovascular diseases. This medication is effectively used to reduce various types of dyslipidemia and the risk of cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; the dose may be adjusted to the maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled with this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients.

Child dose

Age 10 ~ 17 years: The usual dose range is 5mg ~ 20 mg once daily. (There are no clinical data on administration of doses higher than 20mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

It is crucial not to administer this medication to certain patients. For example, patients who are allergic to any of its components, have severe liver dysfunction, or have muscle diseases should not take this medication. Additionally, patients with significantly impaired kidney function, women who are pregnant or breastfeeding, and fertile women who do not use adequate contraception should not use this medication. Patients at high risk of muscle problems should avoid high doses of this medication, and those with certain genetic disorders such as lactose intolerance should not take it. Regular monitoring of liver function and muscle status is required while on this medication. Particularly, individuals with a history of liver disease or those who consume alcohol excessively should exercise extra caution, and if symptoms like muscle pain or weakness occur, they should notify their doctor immediately. This medication may interact with other drugs; therefore, patients must inform their healthcare provider about any other medications they are taking. Women of childbearing potential should ensure thorough contraception while taking this medication and should discontinue usage immediately if pregnancy is confirmed. In case of overdose, there are no specific antidotes, and appropriate treatment and testing based on symptoms are necessary. Furthermore, while this medication does not significantly impact the ability to drive or operate machinery, caution should be exercised as dizziness may occur. Lastly, this medication may rarely cause serious skin reactions, liver damage, or muscle problems in some patients; if any unusual symptoms arise, immediate consultation with a healthcare provider is essential.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug rash resembling erythema multiforme, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, sensory disturbances, chest discomfort, loss of appetite, abdominal distension, fainting, generalized pain, fatigue, joint pain, muscle weakness, convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It is also advisable to store it at room temperature between 1 degree and 30 degrees Celsius. This way, the ingredients of the medication remain unchanged and safe for use.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/bottle, 30 tablets (15 tablets/PTP×2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.